Merck & Company Inc (MRK)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)Advanced Triple-Negative Breast Cancer (TNBC)
📉 **NEGATIVE** • Medium confidence analysis (71%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General